2023 年 54 巻 4 号 p. 173-180
Recently, patient and public involvement (PPI) have gained attention in drug development, and the pharmaceutical industry has been active in incorporating patients' opinions using various methods. To accelerate patient participation in drug development, it is important to increase mutual understanding between the pharmaceutical industry and patients regarding drug development and clinical trials.
We have launched the Clinical Trial Ambassador project, a patient education project conducted by multiple stakeholders, including patient groups, academia, Site Management Organizations (SMOs), and pharmaceutical companies, to raise awareness of clinical trials and provide easy-to-understand information on clinical trials. This report introduces the Clinical Trial Ambassador project and its implementation challenges and future prospects in Japan.
The project aims to create a “sustainable social system” as a platform for patient participation and promote the co-creation of drug development between the pharmaceutical industry and the public.